The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Monoclonal Antibody Biologics and Biosimilars Market Research Report 2024
Synopsis
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Global Monoclonal Antibody Biologics and Biosimilars market is projected to reach US$ 460510 million in 2029, increasing from US$ 216310 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monoclonal Antibody Biologics and Biosimilars market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Monoclonal Antibody Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Innovent Biologics
Segment by Type
Biologics
Biosimilars
Segment by Application
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monoclonal Antibody Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Global Monoclonal Antibody Biologics and Biosimilars market is projected to reach US$ 460510 million in 2029, increasing from US$ 216310 million in 2022, with the CAGR of 12.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Monoclonal Antibody Biologics and Biosimilars market research.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Monoclonal Antibody Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Innovent Biologics
Segment by Type
Biologics
Biosimilars
Segment by Application
Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Monoclonal Antibody Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Monoclonal Antibody Biologics and Biosimilars Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Perspective (2018-2029)
2.2 Monoclonal Antibody Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Region (2024-2029)
2.3 Monoclonal Antibody Biologics and Biosimilars Market Dynamics
2.3.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
2.3.2 Monoclonal Antibody Biologics and Biosimilars Market Drivers
2.3.3 Monoclonal Antibody Biologics and Biosimilars Market Challenges
2.3.4 Monoclonal Antibody Biologics and Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal Antibody Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Monoclonal Antibody Biologics and Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Monoclonal Antibody Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Monoclonal Antibody Biologics and Biosimilars Revenue
3.4 Global Monoclonal Antibody Biologics and Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal Antibody Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody Biologics and Biosimilars Revenue in 2022
3.5 Monoclonal Antibody Biologics and Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal Antibody Biologics and Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal Antibody Biologics and Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal Antibody Biologics and Biosimilars Breakdown Data by Type
4.1 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Type (2024-2029)
5 Monoclonal Antibody Biologics and Biosimilars Breakdown Data by Application
5.1 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Monoclonal Antibody Biologics and Biosimilars Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size (2018-2029)
6.2 North America Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2018-2023)
6.4 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size (2018-2029)
7.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2018-2023)
7.4 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size (2018-2029)
8.2 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2018-2023)
8.4 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Monoclonal Antibody Biologics and Biosimilars Market Size (2018-2029)
9.2 Latin America Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2018-2023)
9.4 Latin America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size (2018-2029)
10.2 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2018-2023)
10.4 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Monoclonal Antibody Biologics and Biosimilars Introduction
11.1.4 Roche Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Monoclonal Antibody Biologics and Biosimilars Introduction
11.2.4 Amgen Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Monoclonal Antibody Biologics and Biosimilars Introduction
11.3.4 AbbVie Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Monoclonal Antibody Biologics and Biosimilars Introduction
11.4.4 Sanofi Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Introduction
11.5.4 Johnson & Johnson Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Monoclonal Antibody Biologics and Biosimilars Introduction
11.6.4 Pfizer Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Detail
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Introduction
11.7.4 Eli Lilly Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.7.5 Eli Lilly Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Monoclonal Antibody Biologics and Biosimilars Introduction
11.8.4 Novartis Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.8.5 Novartis Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Monoclonal Antibody Biologics and Biosimilars Introduction
11.9.4 Merck Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.9.5 Merck Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Monoclonal Antibody Biologics and Biosimilars Introduction
11.10.4 Biogen Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.10.5 Biogen Recent Development
11.11 Celltrion
11.11.1 Celltrion Company Detail
11.11.2 Celltrion Business Overview
11.11.3 Celltrion Monoclonal Antibody Biologics and Biosimilars Introduction
11.11.4 Celltrion Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.11.5 Celltrion Recent Development
11.12 Sobi
11.12.1 Sobi Company Detail
11.12.2 Sobi Business Overview
11.12.3 Sobi Monoclonal Antibody Biologics and Biosimilars Introduction
11.12.4 Sobi Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.12.5 Sobi Recent Development
11.13 3SBIO
11.13.1 3SBIO Company Detail
11.13.2 3SBIO Business Overview
11.13.3 3SBIO Monoclonal Antibody Biologics and Biosimilars Introduction
11.13.4 3SBIO Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.13.5 3SBIO Recent Development
11.14 Innovent Biologics
11.14.1 Innovent Biologics Company Detail
11.14.2 Innovent Biologics Business Overview
11.14.3 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Introduction
11.14.4 Innovent Biologics Revenue in Monoclonal Antibody Biologics and Biosimilars Business (2018-2023)
11.14.5 Innovent Biologics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
